keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal implant

keyword
https://www.readbyqxmd.com/read/28337065/acute-bacterial-endophthalmitis-following-intravitreal-dexamethasone-implant-a-case-report-and-review-of-literature
#1
Neha Goel
Endophthalmitis following intravitreal dexamethasone (DEX) implant has been rarely reported. This report describes the case of a 70-year-old male who underwent intravitreal DEX implant injection under aseptic conditions, for diabetic macular edema. He developed a clinical picture suggestive of endophthalmitis within 2 weeks of the injection, and vitreous culture grew coagulase negative Staphylococcus. He was treated with intravitreal antibiotics followed by pars plana vitrectomy and removal of the implant...
January 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28336283/-early-efficacy-of-dexamethasone-implant-ozurdex-%C3%A2-in-diabetic-macular-edema-real-life-study
#2
V Sarda, F Fajnkuchen, S Nghiem-Buffet, T Grenet, G Chaine, A Giocanti-Auregan
PURPOSE: To assess early efficacy of dexamethasone intravitreal implant 0.7mg (OZURDEX(®)) at the time of peak efficacy (2 months after injection) in patients with decreased visual acuity secondary to diabetic macular edema (DME). MATERIALS AND METHODS: Retrospective monocentric study. Inclusion criteria were best-corrected visual acuity (BCVA)≤70 letters (20/40) due to DME and central retinal thickness (CRT)≥300 microns (Cirrus 2, Carl Zeiss Meditec, Inc, Dublin)...
March 20, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#3
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28333897/comparison-of-surgical-outcome-after-ahmed-valve-implantation-for-patients-with-and-without-fluocinolone-intravitreal-implant-retisert
#4
Eugene A Lowry, Lauren Hennein, Ying Han
No abstract text is available yet for this article.
March 22, 2017: Journal of Glaucoma
https://www.readbyqxmd.com/read/28318718/-treatment-of-macular-edema-comparison-of-efficacy-and-tolerability-of-subconjunctival-triamcinolone-injections-sub-tenon-s-triamcinolone-injections-and-intravitreal-dexamethasone-implant
#5
C Carbonnière, C Couret, A Blériot, O Lebreton, H Massé, G Le Meur, P Lebranchu, M Weber
The area of uveitis is related to numerous pathological entities. One of the main causes of decreased visual acuity in these patients is macular edema. One aspect of the treatment includes cortosteroids used peri- and intra-ocularly. MATERIALS AND METHODS: The goal of our work was to estimate the criteria of efficacy (on improvement in visual acuity and macular edema, as well as time to recurrence) and safety (on intraocular pressure and cataract) of these various routes of administration of corticosteroid after a single injection...
March 16, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28304383/treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#6
D Călugăru, M Călugăru
No abstract text is available yet for this article.
March 17, 2017: Eye
https://www.readbyqxmd.com/read/28283896/fluocinolone-acetonide-intravitreal-implant-0-19%C3%A2-mg-iluvien-%C3%A2-a-review-in-diabetic-macular-edema
#7
Yahiya Y Syed
Fluocinolone acetonide intravitreal implant 0.19 mg (ILUVIEN(®)) is a nonbiodegradable, injectable, corticosteroid implant that is approved in several countries, including the USA, for the treatment of diabetic macular edema (DME). ILUVIEN(®) releases fluocinolone acetonide at an initial rate of 0.25 µg/day (average rate 0.2 µg/day) and lasts 36 months. In the two pooled pivotal FAME trials in patients with DME previously treated with macular laser photocoagulation, fluocinolone acetonide intravitreal implant 0...
March 10, 2017: Drugs
https://www.readbyqxmd.com/read/28272283/dexamethasone-intravitreal-implant-vs-ranibizumab-in-the-treatment-of-macular-edema-secondary-to-brachytherapy-for-choroidal-melanoma
#8
Andrea Russo, Michele Reibaldi, Teresio Avitabile, Maurizio G Uva, Livio Marco Franco, Caterina Gagliano, Vincenza Bonfiglio, Corrado Spatola, Giuseppe Privitera, Antonio Longo
PURPOSE: To evaluate the efficacy of an intravitreal dexamethasone (Dex) implant 0.7 mg compared with intravitreal ranibizumab (Ra) for the treatment of radiation maculopathy with macular edema secondary to plaque brachytherapy in choroidal melanoma. METHODS: Eight patients were treated with intravitreal Ra, and eight patients received the Dex intravitreal implant. Visual acuity and foveal thickness were evaluated using spectral domain optical coherence tomography...
March 7, 2017: Retina
https://www.readbyqxmd.com/read/28263264/value-of-intravitreal-gas-injection-with-ahmed-valve-implantation-in-the-prevention-of-suprachoroidal-hemorrhage-in-aphakic-aniridic-and-vitrectomized-glaucomatous-eyes-a-pilot-study
#9
Heba M A El-Saied, Abdussalam M Adullatif
PURPOSE: The aim of this study was to assess the value of intravitreal injection of nonexpansile C3F8 12% in the prevention of suprachoroidal hemorrhage (SCH) after Ahmed valve implantation for the treatment of secondary glaucoma in vitrectomized, aphakic, and aniridic eyes following blunt trauma. PATIENTS AND METHODS: This is a case series of 5 patients who presented with traumatic secondary glaucoma in vitrectomized, aphakic, and aniridic eyes. Vitrectomy was performed in all eyes after trauma for the treatment of the vitreous hemorrhage...
March 3, 2017: Journal of Glaucoma
https://www.readbyqxmd.com/read/28255227/five-year-outcomes-of-pars-plana-vitrectomy-for-macular-edema-associated-with-branch-retinal-vein-occlusion
#10
Akihiro Nishida, Hiroshi Kojima, Takanori Kameda, Michiko Mandai, Yasuo Kurimoto
PURPOSE: Long-term outcomes of pars plana vitrectomy (PPV) for macular edema (ME) associated with branch retinal vein occlusion (BRVO) have been previously reported, but the studies did not report the number of additional treatments after surgery. During 5 years of follow-up, we therefore investigated the efficacy and safety of PPV for BRVO and evaluated the incidence of additional treatments. METHODS: We retrospectively reviewed the medical records of 25 eyes of 24 patients who underwent PPV for ME associated with BRVO and were followed up for at least 5 years...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28228411/retinal-vascular-calibre-changes-after-intravitreal-bevacizumab-or-dexamethasone-implant-treatment-for-diabetic-macular-oedema
#11
Sanjeewa S Wickremasinghe, Samantha Fraser-Bell, Elizabeth Alessandrello, Hemal Mehta, Mark C Gillies, Lyndell L Lim
PURPOSE: To compare changes in retinal vascular calibre after 2 years of treatment with intravitreal bevacizumab (BVZ) or dexamethasone implant (DEX) in patients with centre-involving diabetic macular oedema (DMO). METHODS: At baseline, 88 eyes of 61 patients with DMO were recruited in a prospective, multicentre, randomised, single-masked clinical trial. Of these subjects, 22 BVZ-treated (52%) and 22 DEX-treated (48%) eyes of 34 patients (56%) had gradable retinal photographs at both the baseline and 24-month visits...
February 22, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28224388/ocular-safety-of-intravitreal-clindamycin-hydrochloride-released-by-plga-implants
#12
Gabriella M Fernandes-Cunha, Silvia Ligório Fialho, Gisele Rodrigues da Silva, Armando Silva-Cunha, Min Zhao, Francine Behar-Cohen
BACKGROUND: Drug ocular toxicity is a field that requires attention. Clindamycin has been injected intravitreally to treat ocular toxoplasmosis, the most common cause of eye posterior segment infection worldwide. However, little is known about the toxicity of clindamycin to ocular tissues. We have previously showed non intraocular toxicity in rabbit eyes of poly(lactic-co-glycolic acid) (PLGA) implants containing clindamycin hydrochloride (CLH) using only clinical macroscotopic observation...
February 21, 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28221257/intravitreal-dexamethasone-implant-in-retinitis-pigmentosa-related-cystoid-macular-edema
#13
Ahmad M Mansour, Huda Sheheitli, Cem Kucukerdonmez, Robert A Sisk, Raphael Moura, Marilita M Moschos, Luiz H Lima, Laila Al-Shaar, J Fernando Arevalo, Mauricio Maia, Robert E Foster, Ozcan Kayikcioglu, Igor Kozak, Shree Kurup, Hernando Zegarra, Roberto Gallego-Pinazo, Rola N Hamam, Riad A Bejjani, Esat Cinar, Ethem T Erakgün, Alan Kimura, Anderson Teixeira
PURPOSE: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. METHODS: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test...
February 17, 2017: Retina
https://www.readbyqxmd.com/read/28218368/intravitreal-dexamethasone-implant-ozurdex%C3%A2-for-exudative-retinal-detachment-after-proton-beam-therapy-for-choroidal-melanoma
#14
Ariane Malclès, Anh-Minh Nguyen, Thibaud Mathis, Jean-Daniel Grange, Laurent Kodjikian
PURPOSE: To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT). METHODS: Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile...
February 8, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28208166/incidence-and-visual-outcomes-of-culture-proven-endophthalmitis-following-dexamethasone-intravitreal-implant
#15
Maxwell S Stem, Bozho Todorich, Yoshihiro Yonekawa, Antonio Capone, George A Williams, Alan J Ruby
Importance: The rate of endophthalmitis following dexamethasone intravitreal implant (DEX) has varied in large clinical trials. Furthermore, to our knowledge, the optimal management of eyes with endophthalmitis associated with DEX has not been established. Objective: To report the incidence of culture-proven endophthalmitis in a single vitreoretinal practice over the course of 3 years and describe the clinical outcomes associated with each case of endophthalmitis...
February 16, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28203186/real-life-iluvien-fluocinolone-acetonide-case-study-rapid-drying-of-the-macula-and-improved-vision-within-2-years-after-therapy-initiation
#16
Hibba Quhill, Fahd Quhill
IMPORTANCE: A case showing sustained structural and functional responses 2 years after a single treatment with ILUVIEN (0.2 µg/day fluocinolone acetonide, FAc) despite suboptimal responses to ranibizumab. OBSERVATIONS: A 68-year-old female patient with diabetic macular oedema (DME) from type 2 diabetes mellitus was first diagnosed in October 2010 and had a baseline visual acuity (VA) of 46 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye...
September 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28196056/effect-of-an-intravitreal-dexamethasone-implant-on-diabetic-macular-edema-after-cataract-surgery
#17
Pilar Calvo, Antonio Ferreras, Fadwa Al Adel, Wantanee Dangboon, Michael H Brent
PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled...
February 10, 2017: Retina
https://www.readbyqxmd.com/read/28195619/efficacy-of-the-intravitreal-sustained-release-dexamethasone-implant-for-diabetic-macular-edema-refractory-to-anti-vascular-endothelial-growth-factor-therapy-meta-analysis-and-clinical-implications
#18
Zainab Khan, Robin K Kuriakose, Maryam Khan, Eric K Chin, David R P Almeida
BACKGROUND AND OBJECTIVE: To assess the effect on best-corrected visual acuity (BCVA) and efficacy of the intravitreal sustained-release 0.7 mg dexamethasone implant (Ozurdex; Allergan, Irvine, CA) in patients with recalcitrant diabetic macular edema (DME). PATIENTS AND METHODS: Meta-analysis utilizing the MOOSE framework and a random effects model. Studies included adults undergoing treatment with Ozurdex for DME. The methodologic quality of each study was assessed using the MINORS and the Cochrane Collaboration Risk of Bias for randomized studies...
February 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28185180/primary-iris-claw-iol-retrofixation-with-intravitreal-triamcinolone-acetonide-in-cases-of-inadequate-capsular-support
#19
Aditya Kelkar, Rachana Shah, Viraj Vasavda, Jai Kelkar, Shreekant Kelkar
PURPOSE: To assess the outcomes and analyze complication rates following primary iris claw IOL retrofixation with intravitreal triamcinolone acetonide. METHODS: This is a retrospective interventional case series. Patients with poor capsular support-diagnosed preoperatively or owing to intraoperative complications-were treated with iris claw IOL retrofixation with intravitreal triamcinolone acetonide. The data were retrospectively analyzed. RESULTS: 104 eyes of 102 patients with poor capsular support who underwent the procedure between 2010 and 2013 were analyzed...
February 9, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28165610/diabetic-macular-edema-outcomes-in-eyes-treated-with-fluocinolone-acetonide-0-2-%C3%A2%C2%B5g-d-intravitreal-implant-real-world-uk-experience
#20
Ibraheem El-Ghrably, David H W Steel, Maged Habib, Daniela Vaideanu-Collins, Sridhar Manvikar, Roxane J Hillier
PURPOSE: To conduct an observational, multicenter study to evaluate real-world clinical efficacy and safety of the 0.2 µg/day fluocinolone acetonide (FAc) implant in the treatment of patients with chronic diabetic macular edema (DME) in 3 large hospital ophthalmology departments in the United Kingdom. METHODS: Fluocinolone acetonide implants were inserted into the study eyes following a suitable washout period; phakic eyes received FAc implant following cataract surgery...
February 6, 2017: European Journal of Ophthalmology
keyword
keyword
99632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"